Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (5)

1

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

enthalten in: The oncologist | 2022

von Moskovitz, M. | Dudnik, E. | Shamai, S. | +13

2

Lung Cancer in Young Patients : Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

enthalten in: Journal of global oncology | 2019

von Suidan, A. | Roisman, L. | Belilovski Rozenblum, A. | +4

3

Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer : Findings from the Real-Life Cohort

enthalten in: Oncology research and treatment | 2019

von Bedas, A. | Peled, N. | Maimon Rabinovich, N. | +8

4

ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism

enthalten in: Clinical lung cancer | 2017

von Zer, A. | Moskovitz, M. | Hwang, D. | +13

CommentIn: Clin Lung Cancer. 2018 Jan;19(1):e71-e72. - PMID 28818428

5

Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy

enthalten in: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia | 2016

von Dudnik, E. | Siegal, T. | Zach, L. | +6

1
[1]